drugset / Trial / NCT00248339

Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection

NCT00248339

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if the use of epoetin-alpha will allow patients with chronic hepatitis C virus infection to be treated with higher doses of peginterferon-alpha-2b and ribavirin, thus increasing chances at lower viral levels and raising sustained virologic response.

Timeline

Start
2002-05
Primary completion
2005-07
Completion
2005-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ribavirin Small molecule 13.3 mg/kg
Comparator Ribavirin Small molecule 15.2 mg/kg
Comparator epoetin alfa Protein / enzyme biologic 40000 iu
Comparator Peginterferon alfa-2b Protein / enzyme biologic 1.5 ug/kg